



1741/1644

Attorney Docket No. P71167US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Ahmed SHERIFF et al.

Serial No. 10/572,875

Art Unit: 1644

Filed: June 21, 2005

Examiner: Sharon X. Wen

For: COMPOUNDS FOR NEUTRALIZING THE EFFECTS OF SECRETED PLA2 IIA

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure references are cited on the attached Form PTO-1449 and, consistent with PTO Rules, copies of cited references are provided. Relevance of cited references is indicated in the attached examination report from a foreign patent office in a counterpart foreign application.

This paper is being filed before first action on the merits or within 3 months of the application filing date or date of entry into the national stage. Accordingly, no fee is required. Should a fee be required, please charge it to Deposit Account No. 06-1358.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By:

William E. Player

Reg. No. 31,409

400 Seventh Street, N.W.
Washington, DC 20004
Tel. (202) 638-6666
Fax (202) 393-5350
Date: August 30, 2007
WEP/jhr

R:\WPLAYE\wep&secretary\2007\August\P71167US0 IDS.wpd

Sheet 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Attorney Docket - P71167US0

Application No. - 10/572,875

Applicant - SHERIFF et al.

Filing Date - June 21, 2006

U.S. PATENT DOCUMENTS

| Examiner [†] | Ref. # | Document No. | Date | Patentee/Applicant |
|-----------------------|--------|--------------|------|--------------------|
| | | | | |
| | | | | |
| | | | | |

FOREIGN PATENT DOCUMENTS

| | Country | Document No. | Translation | Abstract | Date | Patentee |
|--|---------|--------------|--------------------------|--------------------------|------|----------|
| | | | <input type="checkbox"/> | <input type="checkbox"/> | | |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | | |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | | |

NON-PATENT DOCUMENTS

| Examiner [†] | Ref. # | Author (in CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages) |
|-----------------------|--------|--|
| | | P. N. BERNATCHEZ et al., "VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A ₂ ," British Journal of Pharmacology (2001) 134, 197-205 |
| | | M. McCORD et al., "Human Keratinocytes Possess an <i>sn</i> -2 Acylhydrolase that is Biochemically Similar to the U937-Derived 85-kDa Phospholipase A ₂ ," The Journal of Investigative Dermatology, Vol. 102, No. 6, June 1994 |
| | | J. M. STADEL et al., "Recombinant Human Secretory Phospholipase A ₂ : Purification and Characterization of the Enzyme for Active Site Studies," Journal of Molecular Recognition, Vol. 5, 145-153 (1992) |
| | | E. ABRAHAM et al., "Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A ₂ , in patients with suspected sepsis and organ failure," Crit Care Med 2003 Vol. 31, No. 3 |
| | | L. TOUQUI et al., "Mammalian Secreted Phospholipases A ₂ and Their Pathophysiological Significance in Inflammatory Diseases," Current Molecular Medicine 2001, 1, 739-754 |
| | | GENBANK accession No. NM_000300 "Homo sapiens phospholipase A2, group IIA (platelets, synovial fluid) (PLA2G2A), mRNA |
| | | BIDGOOD, J. M., "Type IIA Secretory Phospholipase A ₂ Up-Regulates Cyclooxygenase-2 and Amplifies Cytokine-Mediated Prostaglandin Production in Human Rheumatoid Synoviocytes [†] ," The Journal of Immunology, vol. 165, pgs. 2790-2797 |

Examiner Signature

Date Considered

[†]Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.